Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2014. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of October 31, 2014:
- Total Issued Ordinary Shares: 5,352,245,288 (25p each)
- Treasury Shares: 491,515,950
- Total Voting Rights: 4,860,729,338
This figure is provided to assist shareholders in calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of voting rights (4,860,729,338) against the latest shareholder register.
- Confirm the number of shares held in Treasury (491,515,950) to ensure accurate calculation of free float.
- Check subsequent filings for any changes in share capital or treasury holdings since October 31, 2014.